BRPI0413204A - terapia de combinação para controle glicêmico - Google Patents
terapia de combinação para controle glicêmicoInfo
- Publication number
- BRPI0413204A BRPI0413204A BRPI0413204-1A BRPI0413204A BRPI0413204A BR PI0413204 A BRPI0413204 A BR PI0413204A BR PI0413204 A BRPI0413204 A BR PI0413204A BR PI0413204 A BRPI0413204 A BR PI0413204A
- Authority
- BR
- Brazil
- Prior art keywords
- combination therapy
- glycemic control
- control combination
- diabetes mellitus
- niddm
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 230000002641 glycemic effect Effects 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49953503P | 2003-09-02 | 2003-09-02 | |
| PCT/IB2004/003082 WO2005020983A2 (en) | 2003-09-02 | 2004-09-02 | Combination therapy for glycaemic control |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0413204A true BRPI0413204A (pt) | 2006-10-03 |
Family
ID=34272835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413204-1A BRPI0413204A (pt) | 2003-09-02 | 2004-09-02 | terapia de combinação para controle glicêmico |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060287251A1 (https=) |
| EP (1) | EP1663200A2 (https=) |
| JP (1) | JP2007504213A (https=) |
| KR (1) | KR20060119927A (https=) |
| CN (1) | CN1845731A (https=) |
| AU (1) | AU2004267955A1 (https=) |
| BR (1) | BRPI0413204A (https=) |
| CA (1) | CA2536432A1 (https=) |
| EA (1) | EA200600356A1 (https=) |
| IL (1) | IL173844A0 (https=) |
| MX (1) | MXPA06002127A (https=) |
| NO (1) | NO20061085L (https=) |
| WO (1) | WO2005020983A2 (https=) |
| ZA (1) | ZA200601770B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0526291D0 (en) * | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
| GB0623892D0 (en) * | 2006-11-29 | 2007-01-10 | Medical Res Council Technology | Assay |
| EP2552952A1 (en) * | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
| MX359329B (es) * | 2011-10-28 | 2018-09-25 | Sanofi Aventis Deutschland | Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| DE29924609U1 (de) * | 1999-05-28 | 2004-04-22 | Probiodrug Ag | Neue Effektoren von Dipeptidylpeptidase IV |
| PT1741446E (pt) * | 2000-01-21 | 2008-05-09 | Novartis Pharma Ag | Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos |
| US6890905B2 (en) * | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
| JP2005527504A (ja) * | 2002-02-28 | 2005-09-15 | プロシディオン・リミテッド | グルタミニルを基礎するdpiv阻害剤 |
| WO2004031374A2 (en) * | 2002-09-18 | 2004-04-15 | Prosidion Ltd. | Secondary binding site of dipeptidyl peptidase iv (dp iv) |
-
2004
- 2004-09-02 KR KR1020067004354A patent/KR20060119927A/ko not_active Withdrawn
- 2004-09-02 WO PCT/IB2004/003082 patent/WO2005020983A2/en not_active Ceased
- 2004-09-02 CN CNA2004800251945A patent/CN1845731A/zh active Pending
- 2004-09-02 CA CA002536432A patent/CA2536432A1/en not_active Abandoned
- 2004-09-02 MX MXPA06002127A patent/MXPA06002127A/es not_active Application Discontinuation
- 2004-09-02 AU AU2004267955A patent/AU2004267955A1/en not_active Abandoned
- 2004-09-02 EP EP04769446A patent/EP1663200A2/en not_active Withdrawn
- 2004-09-02 EA EA200600356A patent/EA200600356A1/ru unknown
- 2004-09-02 JP JP2006525215A patent/JP2007504213A/ja not_active Withdrawn
- 2004-09-02 BR BRPI0413204-1A patent/BRPI0413204A/pt not_active IP Right Cessation
- 2004-09-02 US US10/570,113 patent/US20060287251A1/en not_active Abandoned
-
2006
- 2006-02-21 IL IL173844A patent/IL173844A0/en unknown
- 2006-02-28 ZA ZA200601770A patent/ZA200601770B/en unknown
- 2006-03-06 NO NO20061085A patent/NO20061085L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06002127A (es) | 2006-05-31 |
| EA200600356A1 (ru) | 2006-08-25 |
| EP1663200A2 (en) | 2006-06-07 |
| NO20061085L (no) | 2006-05-31 |
| CA2536432A1 (en) | 2005-03-10 |
| US20060287251A1 (en) | 2006-12-21 |
| JP2007504213A (ja) | 2007-03-01 |
| WO2005020983A3 (en) | 2005-07-28 |
| KR20060119927A (ko) | 2006-11-24 |
| IL173844A0 (en) | 2006-07-05 |
| ZA200601770B (en) | 2007-07-25 |
| WO2005020983A2 (en) | 2005-03-10 |
| AU2004267955A1 (en) | 2005-03-10 |
| CN1845731A (zh) | 2006-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004110375A3 (en) | Combination therapy for the treatment of diabetes | |
| BRPI0410731A (pt) | composto, composição farmacêutica, métodos para agonizar o receptor mc4, para tratar obesidade, para tratar diabetes melito e para tratar disfunção sexual masculina e/ou feminina em um mamìfero, e, uso de um composto | |
| BRPI0414062A (pt) | uso de ciclosporinas midificadas para o tratamento de distúrbios por hcv | |
| NO20071144L (no) | Middel for a tilveiebringe substrater basert pa cellulose og/eller stivelse med vannfrastotende og samtidig soppdrepende, antibakterielle, insektfrastotende og algemotvirkende egenskaper | |
| WO2008016648A3 (en) | Certain chemical entities, compositions and methods | |
| BR0206847A (pt) | Tratamento do diabete melito | |
| CL2006003672A1 (es) | Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad. | |
| PT1143955E (pt) | Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete | |
| BR0313792A (pt) | Utilização de proteìna de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento | |
| BRPI0801078A2 (pt) | processo para relaxar ou alisar os cabelos | |
| BRPI0415781A (pt) | método para o tratamento de diabetes em um paciente e kit farmacêutico | |
| BRPI0417451A (pt) | método de tratar um tumor resistente a interferon | |
| IL186356A0 (en) | Method of treating of preventing type-2 diabetes | |
| BRPI0413204A (pt) | terapia de combinação para controle glicêmico | |
| BRPI0414386A (pt) | composto, métodos para fabricação do mesmo, para tratamento ou prevenção de uma doença, para ativação da função de er em uma célula óssea, para inibição de função de er em uma célula, para inibição da expressão de il-6, para inibição do crescimento de uma célula neoplásica expressando er, para prevenção de espermatogenese, para prevenção de um efeito reprodutivo adverso associados com exposição a uma falta de equilìbrio hormonal natural ou quìmica ambiental, e, composição | |
| BRPI0412182A (pt) | composição para tratamento e/ou prevenção de disfunções associadas com diabetes melito do tipo 2 e resistência à insulina | |
| BR0103209A (pt) | Uso de ácido fitânico para o tratamento de diabetes | |
| WO2006017171A3 (en) | Methods of diagnosing & treating obesity, diabetes and insulin resistance | |
| BRPI0507194A (pt) | processo para reduzir o conteúdo e cianeto de hidrogênio em misturas compreendendo penteno-nitrilas e cianeto e hidrogênio, e, uso de 1,3-butadieno | |
| BRPI0508084A (pt) | método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo | |
| WO2005053728A3 (de) | Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik | |
| NO20000731D0 (no) | Neisseria-lactodweeinbindingsprotein | |
| BRPI0506793A (pt) | métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5 | |
| WO2005079840A3 (en) | Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome | |
| WO2003103597A3 (en) | Methods of diagnosing & treating diabetes and insulin resistance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |